Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-30T16:07:15.041Z Has data issue: false hasContentIssue false

Concurrent chemoradiotherapy with carboplatin and uracil–ftegafur in patients with stage two (T2 N0 M0) squamous cell carcinoma of the glottic larynx

Published online by Cambridge University Press:  27 March 2006

T Taguchi
Affiliation:
Department of Otorhinolaryngology, Yokohama City University School of Medicine
M Tsukuda
Affiliation:
Department of Otorhinolaryngology, Yokohama City University School of Medicine
Y Mikami
Affiliation:
Department of Otorhinolaryngology, Yokohama City University School of Medicine
C Horiuchi
Affiliation:
Department of Otorhinolaryngology, Yokohama City University School of Medicine
J-I Ishitoya
Affiliation:
Department of Otorhinolaryngology, Yokohama City University Medical Center, Yokohama, Japan
H Katori
Affiliation:
Department of Otorhinolaryngology, Yokohama City University Medical Center, Yokohama, Japan

Abstract

This study aimed to evaluate the efficacy and toxicity of concurrent chemoradiotherapy as a primary treatment modality for larynx preservation in patients with stage two squamous cell carcinoma (SCC) of the glottic larynx. Between February 2000 and August 2003, a total of 20 patients received concurrent chemoradiotherapy. Carboplatin was given intravenously once a week during the period of radiotherapy. The weekly carboplatin dose was based on the area under the curve 1 to 1.25. Uracil–ftegafur (UFT) was given in a daily oral dose of 300 mg as tegafur. Radiotherapy was delivered five days a week using a once-daily fractionation of 2.0 Gray (Gy), to a total dose of 66–72 Gy. The three-year overall survival rate with larynx preservation was 100 per cent.

Concurrent chemoradiotherapy with carboplatin and UFT for stage two SCC of the glottic larynx was safe and effective in improving local control with larynx preservation.

Type
Main Articles
Copyright
© 2006 JLO (1984) Limited

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)